SFA Therapeutics, Inc is a clinical-stage, platform-based biotech with a novel oral small molecule immunomodulatory platform based on Nobel Prize winning research in innate immunity that is focused on chronic inflammatory and autoimmune diseases with significant unmet needs. Our vision is to change Medicine.

SFA Therapeutics is a clinical-stage biotech developing a first-in-class oral small-molecule platform designed to restore immune homeostasis across autoimmune and inflammatory diseases. Our lead program in psoriasis has demonstrated strong clinical proof-of-concept with durable responses and a clean safety profile, supporting rapid advancement into Phase 2/3 development and broad pipeline expansion.